Lineage ‘Optimistic’ About Dry AMD Treatment

January 2, 2020

Lineage released more patient data from an ongoing clinical study of its retinal pigment epithelium (RPE) transplant therapy for treating dry age-related macular degeneration, noting the successful treatment of five patients.

The treatment uses Lineage’s injectable formulation of RPE cells and Gyroscope Therapeutics’ sub-retinal surgical delivery system, which recently received 510(k) clearance.

The patients, all of whom had less advanced disease, were able to read the letters ETDRS on an eye chart better after treatment, with improvements maintained for up to 15 months.

View today's stories